|
The Treatment of H5N1 Avian Influenza Report: Released by
Aethlon Medical
SAN DIEGO---March 15, 2006--Aethlon Medical, Inc. (OTCBB:AEMD - News), a
pioneer in developing therapeutic devices for infectious disease, disclosed
this afternoon that Chairman and CEO, James A. Joyce, has authored a report
entitled; The Treatment of H5N1 Avian Influenza. The content of the report
follows:
Summary
The intent of this paper is to analyze how current options for treating H5N1
Avian Flu infection may influence the commercialization of the Aethlon
Hemopurifier(TM), a therapeutic device targeted to modulate the immune
response and capture circulating H5N1 virus. In the face of an accelerating
pandemic, the present void in effective H5N1 treatments may dictate that the
Hemopurifier(TM), initially proposed as a treatment for drug resistant
patients, evolves into an important first-line treatment role. Mounting
evidence explaining why H5N1 is often fatal to those infected with the virus
reinforces the opportunity of the Hemopurifier(TM) as an essential weapon in
the treatment arsenal against Avian Flu.
More information on Aethlon Medical and the Hemopurifier(TM) technology can
be found at www.aethlonmedical.com.
|
|
